• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Synspira raises $8m for inhaled pulmonary therapies

June 29, 2017 By Sarah Faulkner

SynspiraPrivately-held Synspira said today that raised $8 million from an unnamed private investor to bring its inhaled cystic fibrosis therapy into a Phase I safety study.

The Boston-based company was founded earlier this year and is focused on developing inhaled therapies for pulmonary diseases, including cystic fibrosis, chronic obstructive pulmonary disease and pneumonia. Synspira holds an exclusive field license to Synedgen’s Glycomics Technology platform and its pulmonary delivery assets.

The company’s lead program, SNSP113, is an inhaled glycopolymeric agent that treats exacerbations and infections related to CF, according to Synspira. In preclinical trials, the therapy has reduced viability of a range of antibiotic-resistant bacteria and it appears to disrupt bacteria’s protective biofilm.

SNSP113 also demonstrated in preclinical trials that it can boost the efficacy of approved antibiotics.

“Our goal at Synspira is to deliver on the promise that our technology holds for addressing one of the most intractable challenges facing patients with pulmonary diseases, recalcitrant chronic infections and the resulting inflammation,” founding CEO Shenda Baker said in prepared remarks. “We believe SNSP113’s unique attributes represent a potentially important new therapeutic approach and could dramatically improve the lives of patients living with cystic fibrosis, the lead indication we are studying.”

“The buildup of thick mucus in the lungs and the resultant bacterial infection is a hallmark of cystic fibrosis and is the cause of the lung damage which results in premature death,” Dr. Stuart Elborn, from the Royal Brompton Hospital, added. “By directly disrupting this mucus accumulation and the related bacterial biofilm, Synspira is taking a completely novel approach to treating this debilitating and life-shortening disease. New treatment options such as this are needed to help alleviate the burden of CF on thousands of patients around the world.”

In connection with its funding, Synspira said that Dr. William Wiesmann will join the company as board chairman.

“The launch of Synspira represents a significant milestone in realizing our vision for improving the lives of patients living with pulmonary diseases by leveraging Synedgen’s Glycomics Technology platform,” Wiesmann said. “Synspira is sharply focused on developing important new inhaled glycopolymer therapies for pulmonary disease and will be initiating a Phase 1 clinical trial for SNSP113 early in 2018. We also look forward to exploring additional indications such as pneumonia and chronic obstructive pulmonary disease where the formation of biofilm is a key driver of pulmonary decline.”

Filed Under: Featured, Funding Roundup, Pharmaceuticals, Respiratory Tagged With: synspira

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS